Categories: Health

Glucose Health, Inc. Announces Officer Changes Effective September 30, 2025

 | Source: Glucose Health

BENTONVILLE, Ark., Sept. 26, 2025 (GLOBE NEWSWIRE) — Glucose Health, Inc. (OTC: GLUC) today announced that its Chief Executive Officer and Chief Financial Officer has resigned, effective September 30, 2025, for personal reasons. The resignation was not requested by the Company.

Murray Fleming, the Company’s sole Director, will perform the functions of Chief Executive Officer and Chief Financial Officer in his capacity as Director to provide administrative continuity and will assist shareholders in identifying new officers. This service will continue until one of the following occurs:

  • Permanent successors, if any, are appointed.
  • The Company determines to wind down and cease operations.
  • The Board takes further action with respect to officer appointments.

There were no disagreements with the Company on any matter relating to its operations, policies, or practices.

The Company confirms that day-to-day operations will continue under the Director’s oversight; however, the Company has limited operating capital and uncertain prospects to continue as a going concern.

For further information, please contact:
info@glucosehealthinc.com 

GlobeNews Wire

Recent Posts

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ms. Kazem brings extensive and global expertise…

2 days ago

Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN…

1 week ago

January Commercial Chapter 11 Filings Increase 76% Over 2025

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- There were 956 commercial Chapter 11 filings…

2 weeks ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical…

2 weeks ago

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease

Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA)…

1 month ago

Personar Appoints Former Genius Sports COO Eric Stevens as Chief Operating Officer to Scale Award-Winning Sports Technology Platform

Tuesday 13 January, 2026 LONDON – Tuesday, January 13, 2026 – Personar, the AI sports…

1 month ago